Amgen
Verastem Oncology, Amgen Partner to Study RAF/MEK Inhibitor With Lumakras in NSCLC
Researchers will track the regimen's activity in NSCLC patients with KRAS G12C mutations who haven't received similar therapies and those who have become resistant to them.
New data for KRAS inhibitors in colorectal cancer show promising results when combined with EGFR inhibitors.
UK's MHRA Grants Early Access to Amgen's Lumakras for KRAS-Mutant Lung Cancer
The drug will be available to patients in England through an expedited conditional approval, while NICE completes its appraisal for full approval.
In a new study, Dana-Farber researchers and collaborators explain the myriad molecular reasons why KRAS-mutated cancers develop resistance to targeted therapy.
ASCO Study Details Activity of Amgen's Lumakras, First Approved KRAS-Targeted Drug, in NSCLC
Researchers found that advanced NSCLC patients with a KRAS G12C mutation taking Lumakras were alive for a median of 12.5 months.